Working… Menu

Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03643549
Recruitment Status : Recruiting
First Posted : August 22, 2018
Last Update Posted : February 12, 2020
Oslo University Hospital
St. Olavs Hospital
University Hospital of North Norway
University of Bergen
University of Bonn
University of Oslo
Information provided by (Responsible Party):
Haukeland University Hospital